Elsevier

Pancreatology

Volume 10, Issue 1, April 2010, Pages 33-38
Pancreatology

Are There Prognostic Factors Related to Recurrence in Pancreatic Endocrine Tumors?

https://doi.org/10.1159/000217604Get rights and content

Abstract

Aims: The aim of this study was to evaluate the rate, site, time of recurrence and prognostic factors related to the appearance of recurrences in patients affected by pancreatic endocrine tumors (PETs). Methods: Data from 67 consecutive patients with PETs who underwent R0 resection were analyzed. The prognostic factors considered were: gender, age, type of tumor, presence of symptoms, size of tumor, tumor node metastasis (TNM) stage, WHO classification and adjuvant therapy. Results: The recurrence rate was 24.6%, with a mean time of 7.3 8 4.5 years. The majority were in the liver (75% of cases) and were rarely local (25%). Univariate analysis of the prognostic factors showed that the risk of recurrences is significantly higher in PETs in MEN-1 syndrome, in tumor size 64 cm, in the presence of liver metastases, in TNM stages III–IV and, finally, in PD-Cas and WD-Cas. Multivariate Cox regression analysis showed that only MEN-1 syndrome and the WHO classification were independent predictors of an increased risk of recurrence. Conclusions: Several prognostic factors were related to recurrences in PETs. MEN-1 syndrome and the WHO classification can be considered independent factors of an increased risk of recurrence.

References (16)

There are more references available in the full text version of this article.

Cited by (36)

  • Prognostic factors for relapse in resected gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis

    2021, Cancer Treatment Reviews
    Citation Excerpt :

    Of these 64 datasets, 56 reported on pancreatic NENs only [9,14,16,19-21,23-31,33-60,62-64,66-70,72-75] (12,418 patients), 3 reported on duodenal NENs (155 patients)[18,54,61] and 5 reported on mixed primary sites including pancreatic, gastroduodenal, gastric and small bowel NENs (1,142 patients) [7,15,32,65,71]. Of the 64 datasets included, 24 reported on grade 1–2 tumours only [9,15,16,21,22,29,32,38,40,45,46,48,49,53,54,57,61,64,65,69-71,74] (4,735 patients) and 40 included grade 1–3 tumours [7,13,14,18,19,21-24,27-32,34,35,37-41,43,45-48,51,54-56,59,60,62-64,66,67,69-71,75] (8,980 patients). Of the 63 included studies, 23 studies included patients with metastatic disease that was resected with curative intent in their analyses.

  • Pancreatic Neuroendocrine Neoplasms: Does Sex Matter?

    2020, Trends in Endocrinology and Metabolism
  • Novel scoring system for recurrence risk classification of surgically resected G1/2 pancreatic neuroendocrine tumors - Retrospective cohort study

    2020, International Journal of Surgery
    Citation Excerpt :

    Other than the poor prognosis of patients with pancreatic cancer (approximately 8% for post-diagnosis 5-year survival rate [3]), life expectancy for PanNENs patients seems to be better with 5-year survival rates from 97% for insulinomas to 30% for nonfunctional metastatic tumors [4]. Resection is regarded as the primary approach for localized PanNENs patients [4,5] and disease recurrence ranges from 21% to 42% according to previous studies [6–8]. The World Health Organization (WHO) classified PanNENs into three subgroups based on the proliferation activity of tumor cells and distinguished pancreatic neuroendocrine tumor (PanNET) and pancreatic neuroendocrine carcinoma (PanNEC) in 2010 [9].

  • Clinical, pathological, and demographic factors associated with development of recurrences after surgical resection in elderly patients with neuroendocrine tumors

    2017, Annals of Oncology
    Citation Excerpt :

    The current study addresses this issue to a certain extent by identifying subgroups at higher risk of recurrence: elderly patients with regional stage, higher grade tumors, and those arising in certain primary sites including the pancreas. These findings on association between stage, site, grade and risk of recurrence are in line with prior smaller-scale studies on some NETs [6–10]. Future studies should validate the findings from our study across age groups and primary sites to pave the way for adjuvant trials in these subgroups.

View all citing articles on Scopus
1

Riccardo Casadei, MD Dipartimento di Scienze Chirurgiche e Anestesiologiche, Chirurgia Generale-Minni Alma Mater Studiorum, Università di Bologna, Policlinico S. Orsola-Malpighi Via Massarenti n.9, IT-40138 Bologna (Italy) Tel. +39 051 341 541, Fax +39 051 341 483

View full text